Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

FDA approves Gemzar for first-line treatment of non-small cell lung cancer

Sep. 4, 1998

Coadministration of PNU-156765 and antiandrogen for prostate cancer

Sep. 4, 1998

A reduced deacetylated metabolite of FK-317 is responsible for antitumor activity

Sep. 4, 1998

Receptor-selective retinoids under study at BMS

Sep. 3, 1998

Cytotoxic gigantecin analogue presented at ACS meeting

Sep. 3, 1998

WHI reports design, synthesis and pharmacological evaluation of new agent for glioblastoma

Sep. 3, 1998

FDA advisory committee recommends clearance for Valstar

Sep. 3, 1998

Nolvadex recommended for approval in U.S., to be copromoted by Zeneca and Roche

Sep. 3, 1998

Antitumor imidazoacridone available for licensing from BTG

Sep. 3, 1998

Protegrin analogue safe in cancer patients receiving chemotherapy

Sep. 3, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...